Search for: "WATSON PHARMACEUTICALS "
Results 221 - 240
of 359
Sorted by Relevance
|
Sort by Date
1 Nov 2011, 6:08 am
Birth-control pills containing drospirenone include Bayer’s Yaz, Yasmin, Beyaz, Safyral; Sandoz’s Syeda and Loryna; Barr Laboratories’ Ocella; Watson Pharmaceuticals’ Zarah; and Teva Pharmaceuticals' Loryna. [read post]
26 May 2007, 11:26 pm
"...spokesmen [for BIO] declined to comment for this [Star-Ledger] story.'In terms of impact, the Star-Ledger identified the following issues:# Barr's Seasonale, the extended-cycle birth-control pill, faces generic competition from Watson Pharmaceuticals. [read post]
6 Feb 2008, 3:47 pm
According to the FTC's brief, the case involves agreements between Bayer and generic manufacturers Barr Labs and The Rugby Group (which has since been acquired by Watson Pharmaceuticals). [read post]
31 Oct 2012, 10:31 am
He also represented Watson Pharmaceuticals Inc. in its $5.9 billion purchase of Swiss drug maker Actavis Inc., which was approved by the FTC (with divestitures) earlier in October. [read post]
3 May 2011, 6:30 am
In addition, following the submission of one of the Foundation’s proposals (to Watson Pharmaceuticals, Inc.), the company announced a plan to bring a declassification proposal to a vote at its 2011 annual meeting. [read post]
4 Dec 2011, 9:38 am
Vestura, is manufactured by Watson Pharmaceuticals, containing ethinyl estradiol and drospirenone, a newer “fourth” generation progestin that is only found in the Yaz-family of contraceptives. [read post]
8 Oct 2009, 6:05 am
Reddy’s, Barr and Purepac (Patent Baristas) Renagel (Sevelamer) – US: Genzyme files patent infringement suit against Endo Pharmaceuticals following Para IV challenge (Patent Docs) Roundup Ready cotton seed – US: Monsanto files patent infringement suits against Brent M Hargrove and Larry H Lytle based on defendants’ use of cotton seed produced from earlier planted Roundup Ready cotton seed (Patent Docs) Seroquel (Quetiapine) – US: CAFC:… [read post]
13 Jan 2010, 3:00 am
Cobrek Pharmaceuticals, Inc (Patent Docs) Nexium (Esomeprazole) – US: Teva drops patent challenge following settlement agreement with AstraZeneca over Nexium (IP Factor) (GenericsWeb) Nuvigil (Armodafinil) - US: Mylan confirms first-to-file patent challenge relating to sleep-disorder drug (SmartBrief) Nuvigil (Armodafinil) - US: Cephalon sues Watson for patent infringement following Para IV challenge (Patent Docs) (GenericsWeb) (Patentcircle) Tasigna (Nilotinib) - India:… [read post]
27 Sep 2008, 12:08 am
(Biotech Blog) United States: Patent for generating oxygen in a process that mimics photosynthesis (Competitive info) Products Adderall (Dextroamphetamine/Racemic DL-ampthetamine) - US: Judge denies Sandoz’ bid for summary judgment of non infringement in patent dispute with Shir eover Adderall (Law360) Carbatrol (Carbamazepine) - US: Judge refuses to grant summary judgment to Corepharma in patent dispute with Shire Laboratories over generic Carbatrol (Law360) Clarinex… [read post]
18 Nov 2019, 4:24 am
In recent lawsuits, the defendants have included McKesson Corporation, Cardinal Health, AmerisourceBergen, Purdue Pharma, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Endo International, Teva Pharmaceutical, Allergan (formerly Actavis), Watson Pharmaceuticals, Covidien, Johnson & Johnson, CVS, Walgreens, and Rite Aid. [read post]
15 Jun 2016, 8:08 am
Valvani then traded in advance of public announcements concerning FDA approvals for such companies as Momenta Pharmaceuticals, Watson Pharmaceuticals, and Amphastar Pharmaceuticals. [read post]
25 Jun 2013, 9:51 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
6 Dec 2010, 10:56 am
“Every worker has the right to expect that they will return home safely to their loved ones at the end of their working day,” Watson said. [read post]
28 Jul 2010, 12:06 am
Watson Laboratories, Inc. [read post]
1 May 2009, 9:00 am
(IAM) US: Johnson & Johnson – 5 year exclusivity period would kill incentives to innovate (Patent Docs) US: CHI CEO on patent reform and follow-on biologics legislation (Patent Docs) US: BIO urges Congress on patent reform: First, do no harm (Patent Baristas) US: Pharmaceutical advertising: How to use a domain name to circumvent application of law (Domain Name / Nom De Domaine!) [read post]
9 Apr 2009, 7:52 am
(Part I - Patent Circle) (Part II – Patent Circle) Indian biogenerics on an upswing – US Promoting Innovation and Access to Life-Saving Medicine Act (Patent Baristas) US: Anti-reverse payment legislation Protecting Consumer Access to Generic Drugs Act of 2009 introduced in the House (Patent Docs) US: CAFC clarifies obviousness standard in context of cDNA cloning invention: In re Kubin (Holman's Biotech IP Blog) (Patent Docs) (Hal Wegner) (Philip Brooks' Patent… [read post]
22 Mar 2011, 4:21 pm
General New IP resource for Pharma, Biotech and Chem – Compulsory licences, comparing national requirements (IP Think Tank) WIPO and India partner to protect traditional knowledge from misappropriation (WIPO) UN Rapporteur for the Right to Health asked to intervene in the TPP negotiation (KEI) Patents and doctors, and the USTR TPP text (KEI) Biotech industry losing interest in the therapeutic potential of RNAi (Patent Docs) India: The curious case of the ‘data exclusivity’ volte… [read post]
21 Mar 2011, 2:04 pm
And, thereafter, we will likely see: (1) Teva Pharmaceuticals and Barr Laboratories make an identical label change for Ocella, a generic version of Yasmin, as well as Gianvi, a generic version of YAZ; and, (2) Watson Pharmaceuticals do likewise for Zarah, another generic version of Yasmin. [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent Docs)… [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent… [read post]
